A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors Meeting Abstract
| Authors: | Schwartz, G. K.; Yazji, S.; Mendelson, D. S.; Dickson, M. A.; Johnston, S. H.; Wang, E. W.; Shannon, P.; Pace, L.; Gordon, M. S. |
| Abstract Title: | A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors |
| Meeting Title: | 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | EJC Supplements |
| Volume: | 6 |
| Issue: | 12 |
| Meeting Dates: | 2008 Oct 21-24 |
| Meeting Location: | Geneva, Switzerland |
| ISSN: | 1359-6349 |
| Publisher: | Pergamon-Elsevier Science Ltd |
| Date Published: | 2008-10-01 |
| Start Page: | 120 |
| Language: | English |
| ACCESSION: | WOS:000261221200382 |
| DOI: | 10.1016/s1359-6349(08)72317-6 |
| PROVIDER: | wos |
| Notes: | --- - Meeting Abstract: 383 - Poster - 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - OCT 21-24, 2008 - Geneva, SWITZERLAND - "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
